nach oben

vorheriger Artikel Risk of cancer after long-term therapy of autoi...

nächster Artikel Cutaneous melanoma—The benefit of screening and...

Tipp

HIV-triggered lymphoma

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 3/2019

Autoren:: Dr. Bernd Lorenz Hartmann, Michèle Desiré Atzl

» Jetzt Zugang zum Volltext erhalten

Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

Treatment outcomes of AIDS-related lymphomas (acquired immune deficiency syndrome, ARL) have improved, nearing those reported for HIV-negative (human immunodeficiency virus) cohorts; recommended treatment protocols are herewith presented. The diagnostic approach to lymphoma in patients with HIV should include screening for and treatment of concomitant infections attributed to HIV-related immunosuppression. Appropriate antiretroviral treatment with adjustments for potential drug interactions should be initiated urgently, and recommended antibiotic, antifungal and antiviral prophylaxis commenced.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4(11):e495–e504. PubMedPubMedCentralCrossRef

Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014;28(6):881–90. PubMedPubMedCentralCrossRef

Hunter NB, Vogt S, Ambinder RF. Treatment of HIV-associated lymphomas: the latest approaches for optimizing outcomes. Oncol (willist Park. 2017;31(12):872–7.

Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012;119(14):3245–55. PubMedPubMedCentralCrossRef

Brunnberg U, Hentrich M, Hoffmann C, Wolf T, Hubel K. HIV-associated malignant Lymphoma. Oncol Res Treat. 2017;40(3):82–7. PubMedCrossRef

Schommers P, Gillor D, Hentrich M, Wyen C, Wolf T, Oette M, et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018;103(5):857–64. PubMedPubMedCentralCrossRef

Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251–62. PubMedPubMedCentralCrossRef

Mhlanga JC, Durand D, Tsai HL, Durand CM, Leal JP, Wang H, et al. Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. Eur J Nucl Med Mol Imaging. 2014;41(4):596–604. PubMedPubMedCentralCrossRef

Sathekge M. Differentiation of HIV-associated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry. Eur J Nucl Med Mol Imaging. 2014;41(4):593–5. PubMedCrossRef

10.

The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89(11):3909–18.

11.

Schommers P, Hentrich M, Hoffmann C, Gillor D, Zoufaly A, Jensen B, et al. Survival of AIDS-related diffuse large B‑cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol. 2015;168(6):806–10. PubMedCrossRef

12.

Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538–43. PubMedPubMedCentralCrossRef

13.

Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B‑cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008–16. PubMedPubMedCentralCrossRef

14.

Wilson WH, Sin-Ho J, Pitcher BN, Hsi ED, Friedberg J, Cheson B, et al. Phase III randomized study of R‑CHOP versus DA-EPOCH‑R and molekular analysis of untreated diffuse large B‑cell Lymphoma: CALGB/alliance 50303. Blood. 2016;128(22):469.

15.

Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313–8. PubMedPubMedCentralCrossRef

16.

Xicoy B, Ribera JM, Muller M, Garcia O, Hoffmann C, Oriol A, et al. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. Leuk Lymphoma. 2014;55(10):2341–8. PubMedCrossRef

17.

Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859–64. PubMedCrossRef

18.

Cortes J, Thomas D, Rios A, Koller C, O’Brien S, Jeha S, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94(5):1492–9. PubMedCrossRef

19.

Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–25. PubMedPubMedCentralCrossRef

20.

Kaplan L. Human herpesvirus-8: Kaposi sarcoma, multicentric Castelman disease, and primary effusion lymphoma. Hematol Am Soc Hematol Educ Programm. 2013;2013:103–8. CrossRef

21.

Brimo F, Michel RP, Khetani K, Auger M. Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer. 2007;111(4):224–33. PubMedCrossRef

22.

Galan J, Martin I, Carmona I, Rodriguez-Barbero JM, Cuadrado E, Garcia-Alonso L, et al. The utility of multiparametric flow cytometry in the detection of primary effusion lymphoma (PEL). Cytometry B Clin Cytom. 2018. https://doi.org/10.1002/cyto.b.21637. PubMedCrossRef

23.

Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653–9. PubMedCrossRef

24.

El-Ayass W, Yu EM, Karcher DS, Aragon-Ching JB. Complete response to EPOCH in a patient with HIV and extracavitary primary effusion lymphoma involving the colon: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2012;12(2):144–7. PubMedCrossRef

25.

Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003;21(21):3948–54. PubMedCrossRef

26.

Terasaki Y, Okumura H, Saito K, Sato Y, Yoshino T, Ichinohasama R, et al. HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab. Intern Med. 2008;47(24):2175–8. PubMedCrossRef

27.

Foster WR, Bischin A, Dorer R, Aboulafia DM. Human Herpesvirus type 8‑associated large B‑cell Lymphoma: a nonserous extracavitary variant of primary effusion Lymphoma in an HIV-infected man: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2016;16(6):311–21. PubMedPubMedCentralCrossRef

28.

Waddington TW, Aboulafia DM. Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. Aids Patient Care Stds. 2004;18(2):67–73. PubMedCrossRef

29.

Won JH, Han SH, Bae SB, Kim CK, Lee NS, Lee KT, et al. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol. 2006;83(4):328–30. PubMedCrossRef

30.

Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013;122(7):1233–42. PubMedPubMedCentralCrossRef

31.

Shah NN, Singavi AK, Harrington A. Daratumumab in primary effusion Lymphoma. N Engl J Med. 2018;379(7):689–90. PubMedCrossRef

32.

Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma. 2008;8(5):300–4. PubMedCrossRef

33.

Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS. 2001;15(2):280–2. PubMedCrossRef

34.

Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006;17(12):1849–50. PubMedCrossRef

35.

Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Muller M, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30(33):4117–23. PubMedCrossRef

36.

Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–206. PubMedCrossRef

37.

Wang CC, Thanh C, Gibson EA, Ball-Burack M, Hogan LE, Descours B, et al. Transient loss of detectable HIV‑1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv. 2018;2(23):3479–82. PubMedPubMedCentralCrossRef

38.

Serrao A, Canichella M, De Luca ML, Tartaglia G, Annechini G, D’Elia GM, et al. Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma. Ann Hematol. 2018. https://doi.org/10.1007/s00277-018-3541-0. PubMedCrossRef

39.

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. PubMedPubMedCentralCrossRef

40.

Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood. 2003;101(10):4115–21. PubMedCrossRef

41.

Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011;11(2):185–9. PubMedCrossRef

42.

Ibrahim IF, Shapiro GA, Naina HV. Treatment of HIV-associated plasmoblastic lymphoma: a single-center experience with 25 patients. J Clin Oncol. 2014;32:abstr 8583. CrossRef

43.

Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169(3):352–5. PubMedCrossRef

44.

Guerrero-Garcia TA, Mogollon RJ, Castillo JJ. Bortezomib in plasmablastic lymphoma: a glimpse of hope for a hard-to-treat disease. Leuk Res. 2017;62:12–6. PubMedCrossRef

45.

Balsalobre P, Diez-Martin JL, Re A, Michieli M, Ribera JM, Canals C, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol. 2009;27(13):2192–8. PubMedCrossRef

46.

Diez-Martin JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113(23):6011–4. PubMedCrossRef

47.

Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol. 2015;7(21):2344–51. PubMedPubMedCentralCrossRef

48.

NIH. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents 2019. 2018; http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed: 20.07.2019.

Titel: HIV-triggered lymphoma
Autoren:: Dr. Bernd Lorenz Hartmann
Michèle Desiré Atzl
Publikationsdatum: 15.08.2019
DOI: https://doi.org/10.1007/s12254-019-00518-7
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 3/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Publisher’s Note

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Skin tumours in organ transplant recipients—implications for the plastic surgeon

Immunosuppression after renal transplantation

Risk of cancer after long-term therapy of autoimmune disorders with glucocorticoids or DMARDs—a controversial issue

Immunosuppression and its complications

Highlights on chronic lymphocytic leukemia presented at the 2018 American Society of Hematology Meeting

Post San Antonio: immunotherapy, chemotherapy and new combinations